I must admit it may not have answered the question fully...
in the context of the presumption that the cell killing is by FTO, I still feel we can't just easily treat any myeloma patient as they may or may not be susceptible to FTO treatment. So in this case treating a patient without CDx may potentially not kill the cancer cells better.
in the context that we don't know the MoA of Zantrene being synergistic, then all this speculation is pointless from me.
Ann: Expanded Heart Protection Discovery for Zantrene, page-280
-
- There are more pages in this discussion • 107 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
0.010(0.63%) |
Mkt cap ! $270.9M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.60 | $1.56 | $168.3K | 106.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 51 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |